Page 82 - Timeliness of Infectious Disease Notification & Response Systems - Corien Swaan

80 Chapter 3
Section/topic #
Checklist item
Reported on page #
Risk of bias in individual 12 studies
Describe methods used for assessing risk of bias of individual studies (including specification of n/a whether this was done at the study or outcome level), and how this information is to be used in any
data synthesis.
Summary measures 13 Synthesis of results 14
State the principal summary measures (e.g., risk ratio, difference in means). 59
Risk of bias across studies 15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, n/a selective reporting within studies).
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 60,61 done, indicating which were pre-specified.
Additional analyses 16
RESULTS
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 60,61 exclusions at each stage, ideally with a flow diagram.
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow- 60,61 up period) and provide the citations.
Study selection 17 Study characteristics 18 Risk of bias within studies 19
Present data on risk of bias of each study and, if available, any outcome level assessment (see item n/a 12).
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 60,61 each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Results of individual 20 studies
Synthesis of results 21
Present results of each meta-analysis done, including confidence intervals and measures of 69 consistency.
Present results of any assessment of risk of bias across studies (see Item 15). n/a Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression n/a [see Item 16]).
Risk of bias across studies 22 Additional analysis 23
DISCUSSION
Summarize the main findings including the strength of evidence for each main outcome; consider 72 their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 75 retrieval of identified research, reporting bias).
Summary of evidence 24 Limitations 25 Conclusions 26
Provide a general interpretation of the results in the context of other evidence, and implications for 76 future research.
FUNDING
Describe sources of funding for the systematic review and other support (e.g., supply of data); role of n/a funders for the systematic review.
Funding 27
Describe the methods of handling data and combining results of studies, if done, including measures 57 of consistency (e.g., I2) for each meta-analysis.